Susquehanna International Group
CALT

Susquehanna International Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Susquehanna International Group’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,397
Closed -$210K – 13313
2024
Q2 		$210K Sell
5,397
-4,880
-47% -$134K ﹤0.01% 10252
2024
Q1 		$222K Buy
10,277
+865
+9% +$19.2K ﹤0.01% 10378
2023
Q4 		$243K Buy
+9,412
New +$176K ﹤0.01% 10288

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

Susquehanna International Group's CALT Position: Q3 2024 in Review

Susquehanna International Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 5,397 shares — an estimated $210K sold.

Susquehanna International Group first reported a position in CALT in Q4 2023 and held it in 3 quarters. The position peaked at $243K in Q4 2023. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • Susquehanna International Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 5,397 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $210K.
  • Susquehanna International Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2023 and held it in 3 quarters.
  • Susquehanna International Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $243K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.